Navigation Links
Major breakthrough may pave the way for therapeutic vaccines
Date:12/17/2009

It should be possible to use therapeutic vaccines to create both cheap and effective drugs for diseases like cancer and allergies. One problem in developing such vaccines has previously been the lack of adjuvants, substances that make vaccines more effective. However, there has now been a major breakthrough in this area. The study, led by scientists at Uppsala University, is published in the December issue of the journal Vaccine.

Many of the treatment methods that are developed today for allergies, cancer, and autoimmune diseases are based on the use of so-called monoclonal antibodies. The cost of these protein pharmaceuticals is high, between 15 000 and 150 000 dollars per patient and year, and long periods of treatment are often needed. Therapeutic vaccines contain no pre-produced antibodies but rather stimulate our immune system to produce its own therapeutic antibodies. They are considerably less expensive to manufacture than the drugs that are now being produced.

"Therapeutic vaccines that target the same molecules in the body as the various monoclonal antibodies would enable us to reduce the cost of treatment significantly, and also decrease the number of visits patients need to make to the clinic," says Lars Hellman, professor of molecular and comparative immunology at the Department of Cell and Molecular Biology, Uppsala University, who directed the study.

One of the biggest problems when it comes to developing therapeutic vaccines has been the lack of so-called adjuvants, immune-stimulating substances that are added to boost the effect of the vaccine. Until now, there has been only one adjuvant that is approved for use in humans, and this substance has proven to have little or no effect when the target molecule is endogenous, that is, produced by the body itself. To develop new and more potent adjuvants, researchers from Uppsala University, in collaboration with colleagues from the Shemyakin-Ovchinnikov Institute in Moscow, have performed comprehensive analyses of various potential combinations.

"We have made a very important breakthrough by managing to identify a substance that is biologically degradable and that exhibits considerably higher activity than the adjuvants that have been used in the past," says Lars Hellman.

"These new and highly promising findings are an important step toward developing more cost-effective drugs for some of our major public health diseases," he says.


'/>"/>

Contact: Lars Hellman
lars.hellman@icm.uu.se
46-018-471-4532
Uppsala University
Source:Eurekalert

Related biology news :

1. Oscar Pistorius artificial limbs give him clear, major advantage for sprint running
2. Oberthur Technologies: Major Security Certifications for the Identity Product Range
3. LSU ichthyologist lands major grant to study fish family history
4. USU scientists report major advance in human antibody therapy against deadly Nipah virus
5. NSF grant supports Rutgers-Camden program for science majors
6. A major step in making better stem cells from adult tissue
7. Major discovery opens door to leishmania treatment
8. How mitochondrial gene defects impair respiration, other major life functions
9. BioConference Live Attracts Major Life Science Sponsors
10. Restoring a natural root signal helps to fight a major corn pest
11. Family planning a major environmental impact
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/4/2017)...  CES 2017 – Valencell , the leading ... the launch of two new versions of its ... sensor modules that incorporate the best of Valencell,s ... The two new designs include Benchmark BE2.0, a ... Benchmark BW2.0, a 2-LED version of its original ...
(Date:12/20/2016)... 20, 2016   Valencell , the leading ... STMicroelectronics (NYSE: STM), a global semiconductor leader ... announced today the launch of a new, highly ... that includes ST,s compact SensorTile turnkey ... biometric sensor system. Together, SensorTile and Benchmark deliver ...
(Date:12/15/2016)... and BADEN-BADEN, Germany , December ... leading global financial services provider, today announced an agreement with ... behavioural biometrics, to join forces. The partnership will enable clients ... strategies in compliance with local data protection regulation. ... In order to ...
Breaking Biology News(10 mins):
(Date:1/24/2017)... - BioAmber Inc. (NYSE: BIOA ) announced that, ... the size of the offering by 75% and purchase 3,684,212 ... to purchase 1,842,106 shares of common stock of the Company ... stock (the "Exercise Price"), at a price to the public ... The warrants have a term of four (4) years, exercisable ...
(Date:1/24/2017)... , ... January 24, 2017 , ... ... circumference, and increased serum leptin levels had a positive association with increased prostate ... study published in the International Neurourology Journal involved 571 Korean men who ...
(Date:1/24/2017)... Franklin, MA, USA & Geneva, Switerland (PRWEB) , ... ... ... are pleased to announce the first commercially available malaria Plasmodium falciparum culture panels ... Malaria P. falciparum culture panels, which are available in a range of concentrations ...
(Date:1/24/2017)... , Jan. 24, 2017 /PRNewswire/ - ProMetic Life Sciences ... announced today that its orally active lead drug candidate, ... designation by the UK Medicines and Healthcare Products Regulatory ... A PIM designation is an early ... for the Early Access to Medicines Scheme ("EAMS"), intended ...
Breaking Biology Technology: